NIAID Funding News, July 17, 2024

July 17, 2024 NIAID Funding News Read this full edition online at https://www.niaid.nih.gov/grants-contracts/funding-news?edition=2024-07-17   Feature Articles  Check Whether Your Research Is a Good Fit for ARPA-H The Advanced Research Projects Agency for Health (ARPA-H) aims to advance high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity. Opportunities and Resources Help Strengthen the Pipeline of Antiviral Drugs for the Next Pandemic This opportunity encourages discovery and development of small molecule compounds with activity against viral targets that could be administered orally as monotherapy or in combination with other drugs to treat infections caused by viruses of pandemic potential. Focus of New Opportunity: Mechanisms of Inducing HIV Immunity in Early Life Investigate and advance mechanistic understanding of how immune ontogeny and functionality in early life could be harnessed in the context of HIV vaccines and broadly neutralizing antibodies to protect against acquisition of HIV infection.  Pursue Epigenetic Treatment Strategies Against HBV in HBV/HIV Co-Infection Apply for funding to conduct innovative basic, translational, and clinical research to identify and address epigenetic treatment strategies for achieving hepatitis B virus (HBV) cure in people living with HIV. In The News Share Your Input on Draft Public Access Policy The draft Public Access Policy builds upon NIH's history of providing public access to scholarly publications resulting from the research it supports and proposes additional steps to accelerate access.  A Window into Participant Inclusion in Clinical Research A central goal of NIH policies is to ensure that the demographics of participants in our clinical research will inform clinical practice to benefit people who are affected by the disease or condition under study. News Briefs and Worth Repeating Change in Prior Approval Requirements for SBIR/STTR Recipients to Add a Subaward Funding for Meetings to Support Data Harmonization of Autoimmune Disease Research Advice Corner R01 Renewal Applications: Calculate Your Budget Cap NIAID caps R01 research project grant renewals at 20 percent above the direct costs of the last competing award period, less the costs of certain items like subawards' facilities and adminsitrative costs. Reader Questions "Do subrecipients need to submit progress reports to NIAID?" "For a resubmission application, if I previously received NIAID's agreement to accept assignment of a big grant for the original application, can I use the same acceptance letter?" New Funding Opportunities RFA-AI-24-049, Halting Tuberculosis (TB) Transmission (R01, Clinical Trial Optional) NOT-AI-24-054, Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research NOT-CA-24-055, Notice of Special Interest (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy PA-24-254, Change of Recipient Organization (Type 7 Parent, Clinical Trial Optional) PA-24-253, Successor-in-Interest (Type 6 Parent, Clinical Trial Optional) RFA-AI-24-045, Promoting Innovative Research in Treponema pallidum Pathogenesis (R21, Clinical Trial Not Allowed) PA-24-247, PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Clinical Trial Not Allowed) PA-24-245, PHS 2024-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) Find other announcements at NIAID Opportunities and Announcements. Send suggestions or comments to deaweb@niaid.nih.gov. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.  This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107